# Acne Vulgaris

Treat acne by lesion phenotype, anatomic extent, scarring risk, and treatment response. Combine mechanistically distinct topical agents, avoid antibiotic monotherapy, use brief systemic antibiotic courses when needed, and move promptly to isotretinoin for severe, scar-forming, psychosocially burdensome, or treatment-refractory disease.

**Clinical question:** How should physicians select and escalate acne therapy while minimizing antibiotic exposure and preventing scarring?

Updated: 2026-09-15T23:11:14.028514+00:00

## What matters in practice
- Use a topical retinoid and benzoyl peroxide as core therapies; combine agents with different mechanisms rather than relying on single-agent treatment. [7][17]
- Never use topical or systemic antibiotics alone; pair them with benzoyl peroxide and limit oral antibiotic exposure. [11][17]
- Escalate directly to oral isotretinoin for severe acne, acne causing scarring or major psychosocial burden, or acne that fails standard topical or oral treatment. [7][17]
- Evaluate patients with acne plus hirsutism, virilization, menstrual concerns, or insulin-resistance findings for clinically meaningful androgen excess rather than treating acne in isolation. [13][22]
- For a large, painful inflammatory nodule, intralesional corticosteroid injection is an option for more rapid relief while systemic disease-directed therapy is optimized. [7][17]

## Classify disease by lesion type, extent, and irreversible-harm risk

Document baseline lesions and identify patients who should bypass stepwise topical escalation.

At the initial visit, record inflammatory lesions (papules, pustules, nodules), noninflammatory lesions (open and closed comedones), involved sites, prior treatment response, and psychosocial impact. A practical global framework defines mild disease as predominantly comedonal with few inflammatory lesions, moderate disease as many comedonal and inflammatory lesions, and severe disease as substantial inflammatory disease with papules and pustules predominant and possible nodulocystic lesions. [2][5][6]

Treat palpable nodules as an escalation signal rather than simply a higher lesion count. In FDA acne-study definitions, a nodule is a deep palpable solid lesion greater than 0.5 cm; nodular or cystic disease is at heightened risk for scarring and warrants prompt consideration of isotretinoin rather than repeated topical or antibiotic cycles. [6][7][17]

Ask specifically about treatment-related irritation, product use, adherence, menstrual association, medication exposures, fever, myalgia, arthralgia, and psychological effect. History should also capture virilization features, including hirsutism, androgen-pattern hair loss, deepening voice, or genital enlargement, because these findings redirect the visit toward evaluation of androgen excess. [22]
- Use photographs or a consistent lesion-count/global assessment method at baseline and follow-up; acne trials commonly assess response at 12 weeks, making this a practical interval for judging topical effectiveness. [1][4][6]
- Include face, chest, and back in the examination; truncal involvement increases treatment burden and may alter topical vehicle selection. [13][19]
- Expedite dermatology-directed escalation when scarring, severe nodules, or substantial psychosocial burden is present. [7][17]

*Clinical severity features that change the initial treatment pathway. [2][5][6][7]*

| Presentation | Actionable interpretation | Initial management consequence |
| --- | --- | --- |
| Predominantly open and closed comedones with few papules or pustules | Mild, comedonal-predominant acne. [2][5] | Use a topical retinoid-centered regimen; add benzoyl peroxide when inflammatory lesions are present. [7][17] |
| Many comedones plus papules and pustules without meaningful nodulocystic disease | Moderate mixed acne. [2][5][6] | Use combination topical therapy; add oral doxycycline when inflammatory burden warrants systemic treatment. [7] |
| Numerous inflammatory lesions, nodules, cysts, scarring, or major psychosocial burden | Severe or high-consequence acne. [2][6][7] | Consider oral isotretinoin promptly; inject an isolated large painful lesion if rapid inflammatory relief is needed. [7][17] |
| Acne with hirsutism, alopecia, menstrual concerns, virilization, acanthosis nigricans, obesity, or hypertension | Possible androgen excess or insulin resistance. [13][22] | Perform focused endocrine and reproductive assessment rather than escalating acne treatment alone. [13][22] |

## Build topical regimens around retinoid and benzoyl peroxide therapy

Use combination treatment when lesion phenotype or severity exceeds a limited comedonal presentation.

Topical retinoids and benzoyl peroxide receive strong guideline recommendations and are appropriate foundational therapies for acne management. Topical antibiotics also have a strong recommendation, but should be deployed only within a combination regimen rather than as standalone therapy. [7][17]

For comedonal-predominant disease, select a topical retinoid as the central agent and reassess clinical response at approximately 12 weeks. FDA study programs for adapalene, tretinoin, and tazarotene evaluate treatment response at day 84, and retinoid-associated sun-exposure precautions include sunscreen and protective clothing when sun avoidance is not feasible. [1][4][5]

For mixed inflammatory and comedonal acne, combine a topical retinoid with benzoyl peroxide and consider adding a topical antibiotic when the inflammatory component warrants it. This approach addresses multiple acne pathways while avoiding topical-antibiotic monotherapy, which promotes bacterial resistance. [7][11][17]

Conditional topical alternatives include clascoterone, azelaic acid, and salicylic acid. These are reasonable additions or substitutions when tolerability, patient preference, contraindications, or phenotype makes a standard retinoid-benzoyl peroxide regimen unsuitable, but the guideline strength is lower than for benzoyl peroxide and topical retinoids. [7]
- Apply topical treatment to the acne-prone treatment area rather than individual visible lesions; clinical studies used a thin coating over the face. [6]
- If irritation limits retinoid use, reassess the vehicle, application pattern, and concurrent products before declaring therapeutic failure.
- Avoid combining a topical antibiotic with no benzoyl peroxide component. [11][17]

*Topical selection by dominant lesion pattern and treatment objective. [7][11][17]*

| Clinical target | Preferred topical strategy | Key restriction or escalation point |
| --- | --- | --- |
| Comedones | Topical retinoid-centered therapy. [7] | Reassess at about 12 weeks; persistent inflammatory disease requires combination therapy. [1][4][5] |
| Papules and pustules with comedones | Topical retinoid plus benzoyl peroxide; add topical antibiotic only in combination. [7][17] | Do not prescribe topical antibiotic monotherapy. [11] |
| Need for a nonretinoid adjunct or alternative | Consider clascoterone, azelaic acid, or salicylic acid. [7] | These carry conditional, rather than strong, recommendations. [7] |
| Persistent inflammatory acne despite optimized topical therapy | Add a systemic agent rather than extending ineffective topical-only management. [7] | Pair any oral antibiotic with topical therapy and benzoyl peroxide. [7][17] |

## Use oral antibiotics briefly and reserve isotretinoin for high-consequence disease

Systemic therapy is indicated by inflammatory severity, scarring risk, burden, and inadequate response to topical treatment.

Oral doxycycline is strongly recommended for acne requiring systemic antibiotic therapy. Oral minocycline and sarecycline are conditionally recommended alternatives. Combine systemic antibiotics with topical therapies, including benzoyl peroxide, and limit their duration to reduce resistance and antibiotic-associated complications. [7][17]

Do not use systemic antibiotic monotherapy. A benzoyl peroxide-containing topical regimen should remain in place during oral antibiotic treatment to reduce resistance selection; when the oral antibiotic is stopped, continue nonantibiotic topical therapy for disease control. [11][17]

Oral isotretinoin is strongly recommended for severe acne, acne producing scarring or psychosocial burden, and acne that has failed standard oral or topical therapy. These indications justify referral or treatment planning before serial antibiotic courses create further delay in a patient with active scarring disease. [7][17]

For an individual large inflammatory lesion causing pain or at risk of persistent inflammation, intralesional corticosteroid injection is a guideline-endorsed adjunct for more rapid relief. It treats the focal lesion but does not replace systemic treatment for generalized nodular acne. [7][17]
- Choose doxycycline when oral antibiotic treatment is needed and no patient-specific contraindication redirects selection. [7]
- Use minocycline or sarecycline as conditional alternatives rather than assuming class interchangeability. [7]
- Reassess every patient receiving an oral antibiotic for discontinuation and transition to nonantibiotic maintenance therapy. [7][15][17]
- Move to isotretinoin when scarring, psychosocial burden, severe disease, or failure of standard therapy is documented. [7][17]

### Hormonal therapy in patients with an androgen-responsive pattern

Combined oral contraceptive pills and spironolactone are conditionally recommended systemic options. Consider them in patients for whom hormonal treatment is clinically appropriate, particularly when acne is associated with menstrual flares or other features that raise concern for androgen contribution. [7][13][22]

Before attributing acne to a routine hormonal pattern, assess for hirsutism, androgen-pattern alopecia, virilization, menstrual history, body mass index, blood pressure, and insulin-resistance findings such as acanthosis nigricans or skin tags. A modified Ferriman-Gallwey score greater than 8 supports hirsutism and should prompt focused evaluation for hyperandrogenism. [13]
- Virilization features require evaluation beyond acne-directed therapy. [22]
- Acne alone is common, but acne plus hirsutism or menstrual abnormalities changes the diagnostic pathway. [13][22]

*Systemic treatment decisions for acne vulgaris. [7][11][17]*

| Clinical situation | Treatment choice | Stewardship or escalation rule |
| --- | --- | --- |
| Moderate inflammatory acne inadequately controlled with topical combination therapy | Oral doxycycline with topical therapy and benzoyl peroxide. [7][17] | Do not use oral antibiotic monotherapy; minimize duration. [11][17] |
| Need for an oral tetracycline alternative | Consider oral minocycline or sarecycline. [7] | These are conditional recommendations. [7] |
| Clinically appropriate hormonal treatment candidate | Consider combined oral contraceptive pills or spironolactone. [7] | Assess for androgen-excess features rather than presuming uncomplicated acne. [13][22] |
| Severe, scar-forming, psychosocially burdensome, or treatment-refractory acne | Oral isotretinoin. [7][17] | Do not defer escalation through repeated standard-treatment failures. [7][17] |
| Large painful inflammatory nodule | Intralesional corticosteroid injection as an adjunct. [7][17] | Continue disease-directed therapy for generalized acne. [7][17] |

## Define treatment failure before changing therapy

A regimen can only be judged after correct application, tolerability review, and an adequate assessment interval.

At follow-up, compare lesion counts, global severity, new nodules, truncal involvement, scarring progression, adverse effects, and patient-reported psychosocial burden against baseline. FDA acne trials commonly use lesion counts and investigator global assessments at 12 weeks, but global ratings can vary between investigators; serial use of the same method is more informative than switching scales. [1][2][4][6]

Interpret persistent disease in context. New nodules, scar formation, or worsening psychosocial burden should trigger escalation even if the total lesion count falls. In contrast, irritation, inconsistent use, or unrecognized overlapping topical products should be corrected before labeling a retinoid- or benzoyl peroxide-based regimen ineffective.

After stopping an oral antibiotic, maintain disease control with nonantibiotic topical therapy. Maintenance evidence has been evaluated in randomized trials, and guideline practice emphasizes combination topical therapies and limited systemic antibiotic exposure rather than chronic antibiotic treatment. [7][17][23]
- At each visit, document whether antibiotics remain necessary; continued use requires a clear inflammatory indication and concurrent benzoyl peroxide. [11][17]
- Escalate promptly for active scarring or severe nodular disease rather than using lesion-count improvement alone to justify continued low-intensity therapy. [7][17]
- Reassess endocrine clues when acne remains treatment resistant and is accompanied by hirsutism, menstrual concerns, virilization, or insulin-resistance findings. [13][22]

*Follow-up findings and the next management step. [7][11][13][17][22]*

| Follow-up finding | Interpretation | Next action |
| --- | --- | --- |
| Improved lesions without new nodules or scars | Current regimen is providing disease control. | Continue nonantibiotic topical maintenance strategy. [7][17] |
| Persistent papules and pustules after an adequate topical trial | Inflammatory burden remains undertreated. | Optimize combination topical therapy or add doxycycline with benzoyl peroxide when systemic treatment is indicated. [7][17] |
| New nodules, scars, or major psychosocial burden | High-consequence acne despite current management. | Plan isotretinoin treatment or dermatology escalation. [7][17] |
| Acne plus hirsutism, virilization, menstrual abnormalities, or acanthosis nigricans | Possible hyperandrogenism or insulin resistance. | Perform focused endocrine and reproductive assessment. [13][22] |

## References
1. [PDF] Tretinoin Topical Lotion - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209353.pdf
2. [PDF] Statistical Review and Evaluation Clinical Studies (ACZONE) - FDA — www.fda.gov — https://www.fda.gov/media/104718/download
3. [PDF] Minocycline Hydrochloride Topical Aerosol Foam - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212379.pdf
4. [PDF] Tazarotene Topical Aerosol Foam - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202428.pdf
5. [PDF] Adapalene Topical Lotion - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022502.pdf
6. [PDF] clinical review - FDA — www.fda.gov — https://www.fda.gov/media/71545/download
7. Guidelines of care for the management of acne vulgaris - ScienceDirect — www.sciencedirect.com — http://www.sciencedirect.com/science/article/pii/S0190962223033893
8. Guidelines of care for the management of acne vulgaris — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0190962223033893
9. Guidelines of care for acne vulgaris - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0190962208810456
10. Steroid Injection Treatment for Nodulocystic Acne: A Literature Review - Lee - 2025 - Dermatological Reviews - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1002/der2.70021
11. Analyzing trends in treatment of acne vulgaris and adherence to the American Academy of Dermatology guidelines: A retrospective study — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2666328722001183
12. An overview of treatment options for mild‐to‐moderate acne based on American Academy of Dermatology, European Academy of Dermatology and Venereology, and Italian Society of Dermatology and Venereology guidelines - Conforti - 2020 - Dermatologic Therapy - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/dth.13548
13. Screening and Management of the Hyperandrogenic... : Obstetrics & Gynecology — journals.lww.com — https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000003475~screening-and-management-of-the-hyperandrogenic-adolescent
14. Epidemiological patterns of acne vulgaris among... - Ovid — journals.lww.com — https://journals.lww.com/ijpd/fulltext/2017/18030/epidemiological_patterns_of_acne_vulgaris_among.8.aspx
15. Managing acne vulgaris: an update - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10803966
16. Recent Trends in the Management of Acne Vulgaris: A Review ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11031619
17. American Academy of Dermatology issues updated guidelines for ... — www.aad.org — https://www.aad.org/news/updated-guidelines-acne-management
18. Guidelines of care for the management of acne vulgaris - PubMed — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/38300170
19. Dermatology: how to manage acne vulgaris - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8510514
20. Update to acne vulgaris treatment for Canadian practice - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12312855
21. Isotretinoin - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK525949
22. Acne Vulgaris - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK459173
23. Maintenance treatments for acne vulgaris - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK592054
24. Acne clinical guideline — www.aad.org — https://www.aad.org/member/clinical-quality/guidelines/acne

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.